Fig. 2: Inhibition of c-myc expression induces palbociclib sensitivity.
From: c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis
a MCF-7 and MDA-MB-231 cells were treated with the combination of palbociclib and mycro-3. The dose radio of palbociclib and mycro-3 was 1:1. Cell viability was investigated by Cell Counting kit-8 assay. CI vs. Fa plot (combination index vs. fraction affected) for cell viability data are shown. The CI values were calculated by Compusyn software. CI values below 1 are considered to have a synergistic interaction. b MCF-7 and MDA-MB-231 cells were treated with 1–64 µM palbociclib combined with a constant dose of mycro-3 (9, 18, 36, 72 µM) for 48 h. CI values calculated by Compusyn software are shown. c Cell-cycle analysis of MCF-7 and MDA-MB-231 cells 48 h after treatment with the indicated drugs, Myc plasmid, or shMyc transfection. d Colony formation assays of MCF-7 and MDA-MB-231 cells 14 d after treatment with DMSO or the indicated drugs. Colonies were counted and captured. Representative images and data based on three independent experiments. Error bars indicate mean ± standard deviation.
